Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY)

RDY on New York Consolidated

41.58USD
23 Jun 2017
Change (% chg)

$0.41 (+1.00%)
Prev Close
$41.17
Open
$41.38
Day's High
$41.61
Day's Low
$41.24
Volume
132,928
Avg. Vol
271,774
52-wk High
$54.73
52-wk Low
$37.03

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets
Thursday, 15 Jun 2017 02:03am EDT 

June 15 (Reuters) - Dr.Reddy's Laboratories Ltd :Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US"..Says voluntarily recalled Cipla-made zenatane capsule from US markets.Recall of prodcuts is a usual activity in normal course of business operations.Says overall impact on co's financials of recall not likely to be significant.  Full Article

Dr.Reddy's Labs gets EIR as closure of audit of Miryalaguda API manufacturing plant
Tuesday, 13 Jun 2017 11:05pm EDT 

June 14 (Reuters) - Dr.Reddy's Laboratories Ltd :Says got EIR after audit of API manufacturing plant at Miryalaguda, by US FDA, as closure of audit.  Full Article

Dr.Reddy's Laboratories announces launch of Bivalirudin for injection in U.S. market
Tuesday, 6 Jun 2017 01:48am EDT 

June 6 (Reuters) - Dr.Reddy's Laboratories Ltd :Says announces launch of Bivalirudin for injection in U.S. market.  Full Article

Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations
Thursday, 25 May 2017 08:32am EDT 

May 25 (Reuters) - Dr.Reddy's Laboratories Ltd :Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations..  Full Article

Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.
Wednesday, 17 May 2017 03:15am EDT 

May 17 (Reuters) - Dr.Reddy's Laboratories Ltd :Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market.  Full Article

India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold
Friday, 12 May 2017 03:40am EDT 

May 12 (Reuters) - Dr.Reddy's Laboratories Ltd :Consol March quarter net profit 3.38 billion rupees.Consensus forecast for March quarter consol profit was 4.27 billion rupees.Consol March quarter net sales 34.99 billion rupees.Consol net profit in March quarter last year was 1.23 billion rupees as per Ind-AS; net sales 36.95 billion rupees.Recommended final dividend of 20 rupees per share.Says "FY17 has been a challenging year due to lack of new product approvals for US market".  Full Article

Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market
Thursday, 27 Apr 2017 12:37am EDT 

April 27 (Reuters) - Dr.Reddy's Laboratories Ltd :Says launch of Ezetimibe and Simvastatin tablets in U.S. market.  Full Article

Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India
Monday, 27 Mar 2017 03:02am EDT 

Dr.Reddy's Laboratories Ltd : Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India .Says to market, distribute duragen plus and suturable duragen dural renegration matrices for use in India.  Full Article

Dr Reddys says preparing response on observations received from US FDA
Tuesday, 21 Mar 2017 02:59am EDT 

Dr.Reddy's Laboratories Ltd : Clarifies on news item "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance." .Says preparing response and will submit it to FDA.  Full Article

Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories
Thursday, 16 Mar 2017 07:00am EDT 

Cytosorbents Corp : Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market . Dr. Reddy's has exclusive rights to distribute Cytosorb for intensive care, cardiac surgery, other hospital applications in South Africa . Multi-year agreement is subject to annual minimum purchases of Cytosorb to maintain exclusivity .Financial terms of this agreement have not been disclosed.  Full Article

More From Around the Web

BRIEF-Dr. Reddy's Lab says USFDA issues form 483 with one observation for Srikakulam Plant

* Says formulations Srikakulam Plant (SEZ) unit I, Andhra Pradesh, by US FDA, has been completed Friday